查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1373946

全球德庫姆氏症市場預測（截至2030年）

Dercums Disease Market Research Report Forecast till 2030
出版日期: | 出版商: Market Research Future | 英文 115 Pages | 訂單完成後即時交付

價格

預測期內，全球 Dercum 病市場規模預計將以 6.76% 的複合年增長率成長。

區域考慮

2022年北美市場佔最大市場份額。

歐洲市場佔有第二大市場份額。德國市場佔有最大的市場份額，法國市場是歐洲成長最快的。

預計亞太市場將在2023-2030年間呈現顯著發展。

本報告研究分析了全球 Dercum 病市場，提供市場動態、區域和細分市場分析、公司簡介等。

目錄

第一章執行摘要

第二章市場介紹

第三章研究方法

第四章市場動態

  • 概述
  • 促進者
    • 罕見疾病發生率上升
    • 增加研發活動
  • 抑製劑
    • 人們對這種疾病缺乏認識
  • 機會
    • 增加策略舉措

第五章市場因素分析

  • 價值鏈分析
    • 研究與開發
    • 製造業
    • 銷售、分銷
    • 售後調查
  • 波特五力分析模型
  • COVID-19 對全球皮膚病市場的影響
    • 對供應鏈的影響
    • 對需求的影響
    • 對市場的影響

第六章全球皮膚病市場：依治療分類

  • 概述
  • 手術
  • 劑量
    • 利尿劑
    • 非甾體抗炎藥
    • 皮質類固醇
    • 其他
  • 抽脂術
  • 電療
  • 針刺
  • 其他

第七章全球皮膚病市場：依最終用戶分類

  • 概述
  • 醫院/診所
  • 門診手術中心
  • 其他

第八章全球皮膚病市場：按分銷管道

  • 概述
  • 醫院藥房
  • 零售藥店
  • 其他

第九章全球皮膚病市場：按地區

  • 概述
  • 北美
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 意大利
    • 西班牙
    • 歐洲其他地區
  • 亞太地區
    • 中國
    • 印度
    • 印度
    • 澳大利亞
    • 韓國
    • 亞太其他地區
  • 其他地區
    • 中東
    • 非洲
    • 拉丁美洲

第10章競爭格局

  • 概述
  • 競爭標桿
  • 財務矩陣
    • 銷售額 (2022)
    • 研發費用（2022年）

第十一章公司簡介

  • PFIZER INC
  • ABBVIE, INC
  • JOHNSON & JOHNSON SERVICES, INC
  • GLAXOSMITHKLINE PLC
  • BAUSCH & LOMB INCORPORATED
  • CALIWAY
  • RAZIEL THERAPEUTICS LTD
  • NIVARTA, INC.
  • BHR PHARMACEUTICALS LTD
  • NOVARTIS INTERNATIONAL AG

第十二章附錄

Product Code: MRFR/HC/4889-CR

Market Overview

The Dercum's Disease Market is anticipated to register a CAGR of 6.76% during the forecast period. The rising predominance of interesting diseases and expanding research and advancement exercises are driving market development.

Uncommon diseases, for example, adiposis dolorosa, and lipomas alongside the continuous Coronavirus pandemic, represent a significant weight worldwide. As per the NCBI study, held in February 2021, roughly 2500 individuals each year with free connective (fat) tissue disease were seen, most patients with lipedema, six patients with FML-Type DD, and 10 patients with angiolipoma-type Dercum's disease. Moreover, a similar review recommended that the predominance of Dercum's disease is 0.64% in the populace, and the commonness of lipedema in the USA is believed to be 11% in ladies however the reach is 5 to 39%. A greater part of individuals with dercum's disease are ladies.

Besides, dercum's disease is portrayed by various, agonizing developments of greasy tissue (lipomas). In this way, the quantity of patients experiencing uncommon diseases is expanding universally. Besides, the rising instances of Coronavirus likewise fundamentally affect the market development of the dercum's disease. Such an ascent in the quantity of diseases cases is expected to worldwide expand the interest for dercum's disease.

Market Segmentation

The Market segments of Dercum's Disease, based on treatment, includes surgery, medication, liposuction, electrotherapy, acupuncture, and others.

The Dercum's Disease Market segmentation is based on end user that includes hospital & clinics ambulatory surgical centers others. Based on distribution channel the market is divided into hospital pharmacies, retail pharmacies, and others.

Regional Insights

The North America dercum's disease market represented the biggest market share in 2022. This is because of the ideal government act towards for the improvement of uncommon disease drug and gadgets as well as endorsement of medication in the district.

Europe dercum's disease market represents the second-biggest market share because of the research concentrates on through medical services administrative bodies for the therapy of dercum's disease and ideal approach and public undertakings systems. further, the Germany market of dercum's disease was credited to hold the biggest market share, and the France market of dercum's disease is supposed to quickest developing market in the European locale.

The Asia-Pacific dercum's disease market is supposed to develop at a critical offer from 2023 to 2030. This is because of the rising speculation, clinical preliminary examinations, and organizations' Research and development for medications to treat fat dolorosa in the Asia-Pacific locale.

The Rest of the World is portioned into the Middle East, Africa, and Latin America. The market of dercum's disease in the previously mentioned locales is probably going to observe development because of raising of assets and interests in the area through organizations.

Major Players

Key Companies in the market of dercum's disease include Pfizer Inc (US), Abbvie, Inc (US), Johnson & Johnson Services, Inc (US), GlaxoSmithKline plc (UK), Bausch & Lomb Incorporated (Canada), Caliway (Taiwan), Raziel Therapeutics Ltd (Israel), Nivarta, Inc (US), BHR Pharmaceuticals Ltd (UK), and Novartis International AG (Switzerland).

TABLE OF CONTENTS

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

  • 2.1 DEFINITION
  • 2.2 SCOPE OF THE STUDY
  • 2.3 RESEARCH OBJECTIVE
  • 2.4 LIST OF ASSUMPTIONS & LIMITATIONS

3 RESEARCH METHODOLOGY

  • 3.1 DATA MINING
  • 3.2 SECONDARY RESEARCH
  • 3.3 PRIMARY RESEARCH
    • 3.3.1 PRIMARY INTERVIEWS AND INFORMATION GATHERING PROCESS
    • 3.3.2 BREAKDOWN OF PRIMARY RESPONDENTS
  • 3.4 FORECASTING TECHNIQUES
  • 3.5 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION
    • 3.5.1 BOTTOM-UP APPROACH
    • 3.5.2 TOP-DOWN APPROACH
  • 3.6 DATA TRIANGULATION
  • 3.7 VALIDATION

4 MARKET DYNAMICS

  • 4.1 OVERVIEW
  • 4.2 DRIVERS
    • 4.2.1 RISING PREVALENCE OF RARE DISEASES
    • 4.2.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES
  • 4.3 RESTRAINTS
    • 4.3.1 LACK OF AWARENESS AMONG THE PEOPLE ABOUT THE DISEASE
  • 4.4 OPPORTUNITIES
    • 4.4.1 RISING NUMBER OF STRATEGIC INITIATIVES

5 MARKET FACTOR ANALYSIS

  • 5.1 VALUE CHAIN ANALYSIS
    • 5.1.1 R&D
    • 5.1.2 MANUFACTURING
    • 5.1.3 SALES AND DISTRIBUTION
    • 5.1.4 POST-SALES REVIEW
  • 5.2 PORTER'S FIVE FORCES MODEL
    • 5.2.1 THREAT OF NEW ENTRANTS
    • 5.2.2 BARGAINING POWER OF SUPPLIERS
    • 5.2.3 THREAT OF SUBSTITUTES
    • 5.2.4 BARGAINING POWER OF BUYERS
    • 5.2.5 INTENSITY OF RIVALRY
  • 5.3 IMPACT OF COVID-19 ON THE GLOBAL DERCUM'S DISEASE MARKET
    • 5.3.1 IMPACT ON SUPPLY CHAIN
    • 5.3.2 IMPACT ON DEMAND
    • 5.3.3 IMPACT ON MARKET

6 GLOBAL DERCUM'S DISEASE MARKET, BY TREATMENT

  • 6.1 OVERVIEW
  • 6.2 SURGERY
  • 6.3 MEDICATION
    • 6.3.1 DIURETICS
    • 6.3.2 NON-STEROIDAL ANTI-INFLAMMATORY DRUG
    • 6.3.3 CORTICOSTEROIDS
    • 6.3.4 OTHERS
  • 6.4 LIPOSUCTION
  • 6.5 ELECTROTHERAPY
  • 6.6 ACUPUNCTURE
  • 6.7 OTHERS

7 GLOBAL DERCUM'S DISEASE MARKET, BY END-USER

  • 7.1 OVERVIEW
  • 7.2 HOSPITAL & CLINICS
  • 7.3 AMBULATORY SURGICAL CENTERS
  • 7.4 OTHERS

8 GLOBAL DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL

  • 8.1 OVERVIEW
  • 8.2 HOSPITAL PHARMACIES
  • 8.3 RETAIL PHARMACIES
  • 8.4 OTHERS

9 GLOBAL DERCUM'S DISEASE MARKET, BY REGION

  • 9.1 OVERVIEW
  • 9.2 NORTH AMERICA
    • 9.2.1 US
    • 9.2.2 CANADA
  • 9.3 EUROPE
    • 9.3.1 GERMANY
    • 9.3.2 UK
    • 9.3.3 FRANCE
    • 9.3.4 ITALY
    • 9.3.5 SPAIN
    • 9.3.6 REST OF EUROPE
  • 9.4 ASIA PACIFIC
    • 9.4.1 CHINA
    • 9.4.2 INDIA
    • 9.4.3 INDIA
    • 9.4.4 AUSTRALIA
    • 9.4.5 SOUTH KOREA
    • 9.4.6 REST OF ASIA PACIFIC
  • 9.5 REST OF THE WORLD
    • 9.5.1 MIDDLE EAST
    • 9.5.2 AFRICA
    • 9.5.3 LATIN AMERICA

10 COMPETITIVE LANDSCAPE

  • 10.1 OVERVIEW
  • 10.2 COMPETITIVE BENCHMARKING
  • 10.3 FINANCIAL MATRIX
    • 10.3.1 SALES (USD MILLION), 2022
    • 10.3.2 R&D EXPENDITURE (USD MILLION), 2022

11 COMPANY PROFILES

  • 11.1 PFIZER INC
    • 11.1.1 COMPANY OVERVIEW
    • 11.1.2 FINANCIAL OVERVIEW
    • 11.1.3 PRODUCTS OFFERED
    • 11.1.4 KEY DEVELOPMENTS
    • 11.1.5 SWOT ANALYSIS
    • 11.1.6 KEY STRATEGIES
  • 11.2 ABBVIE, INC
    • 11.2.1 COMPANY OVERVIEW
    • 11.2.2 FINANCIAL OVERVIEW
    • 11.2.3 PRODUCTS OFFERED
    • 11.2.4 KEY DEVELOPMENTS
    • 11.2.5 KEY STRATEGIES
  • 11.3 JOHNSON & JOHNSON SERVICES, INC
    • 11.3.1 COMPANY OVERVIEWS
    • 11.3.2 FINANCIAL OVERVIEW
    • 11.3.3 PRODUCTS OFFERED
    • 11.3.4 KEY DEVELOPMENTS
    • 11.3.5 SWOT ANALYSIS
    • 11.3.6 KEY STRATEGIES
  • 11.4 GLAXOSMITHKLINE PLC
    • 11.4.1 COMPANY OVERVIEW
    • 11.4.2 FINANCIAL OVERVIEW
    • 11.4.3 PRODUCTS OFFERED
    • 11.4.4 KEY DEVELOPMENTS
    • 11.4.5 SWOT ANALYSIS
    • 11.4.6 KEY STRATEGIES
  • 11.5 BAUSCH & LOMB INCORPORATED
    • 11.5.1 COMPANY OVERVIEW
    • 11.5.2 FINANCIAL OVERVIEW
    • 11.5.3 PRODUCTS OFFERED
    • 11.5.4 KEY DEVELOPMENTSS
    • 11.5.5 KEY STRATEGIES
  • 11.6 CALIWAY
    • 11.6.1 COMPANY OVERVIEW
    • 11.6.2 FINANCIAL OVERVIEW
    • 11.6.3 PRODUCTS/SERVICES OFFERED
    • 11.6.4 KEY DEVELOPMENTS
    • 11.6.5 KEY STRATEGIES
  • 11.7 RAZIEL THERAPEUTICS LTD
    • 11.7.1 COMPANY OVERVIEW
    • 11.7.2 FINANCIAL OVERVIEW
    • 11.7.3 PRODUCTS OFFERED
    • 11.7.4 KEY DEVELOPMENTS
    • 11.7.5 KEY STRATEGIES
  • 11.8 NIVARTA, INC.
    • 11.8.1 COMPANY OVERVIEW
    • 11.8.2 FINANCIAL OVERVIEW
    • 11.8.3 PRODUCTS OFFERED
    • 11.8.4 KEY DEVELOPMENTS
    • 11.8.5 SWOT ANALYSIS
    • 11.8.6 KEY STRATEGIES
  • 11.9 BHR PHARMACEUTICALS LTD
    • 11.9.1 COMPANY OVERVIEW
    • 11.9.2 FINANCIAL OVERVIEW
    • 11.9.3 PRODUCTS OFFERED
    • 11.9.4 KEY STRATEGIES
  • 11.10 NOVARTIS INTERNATIONAL AG
    • 11.10.1 COMPANY OVERVIEW
    • 11.10.2 FINANCIAL OVERVIEW
    • 11.10.3 PRODUCTS OFFERED
    • 11.10.4 KEY DEVELOPMENTS
    • 11.10.5 SWOT ANALYSIS
    • 11.10.6 KEY STRATEGIES

12 APPENDIX

  • 12.1 REFERENCES
  • 12.2 RELATED REPORTS

LIST OF TABLES

  • TABLE 1 LIST OF ASSUMPTIONS & LIMITATIONS
  • TABLE 2 GLOBAL: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 3 GLOBAL: DERCUM'S DISEASE MARKET, FOR SURGERY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 4 GLOBAL: DERCUM'S DISEASE MARKET, FOR MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5 GLOBAL: DERCUM'S DISEASE MARKET, FOR MEDICATION, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 6 GLOBAL: DERCUM'S DISEASE MARKET, FOR DIURETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7 GLOBAL: DERCUM'S DISEASE MARKET, FOR NON-STEROIDAL ANTI-INFLAMMATORY DRUG, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8 GLOBAL: DERCUM'S DISEASE MARKET, FOR CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9 GLOBAL: DERCUM'S DISEASE MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10 GLOBAL: DERCUM'S DISEASE MARKET, FOR LIPOSUCTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11 GLOBAL: DERCUM'S DISEASE MARKET, FOR ELECTROTHERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12 GLOBAL: DERCUM'S DISEASE MARKET, FOR ACUPUNCTURE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13 GLOBAL: DERCUM'S DISEASE MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14 GLOBAL: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 15 GLOBAL: DERCUM'S DISEASE MARKET, FOR HOSPITAL & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16 GLOBAL: DERCUM'S DISEASE MARKET, FOR AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17 GLOBAL: DERCUM'S DISEASE MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18 GLOBAL: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 19 GLOBAL: DERCUM'S DISEASE MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20 GLOBAL: DERCUM'S DISEASE MARKET, FOR RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21 GLOBAL: DERCUM'S DISEASE MARKET, FOR OTHERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22 GLOBAL: DERCUM'S DISEASE MARKET, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23 NORTH AMERICA: DERCUM'S DISEASE MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 24 NORTH AMERICA: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 25 NORTH AMERICA: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 26 NORTH AMERICA: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 27 NORTH AMERICA: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 28 US: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 29 US: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 30 US: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31 US: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 32 CANADA: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 33 CANADA: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 34 CANADA: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35 CANADA: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 36 EUROPE: DERCUM'S DISEASE MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 37 EUROPE: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 38 EUROPE: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 39 EUROPE: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40 EUROPE: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 41 GERMANY: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 42 GERMANY: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 43 GERMANY: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 44 GERMANY: DERCUM'S DISEASE MARKET, BY DISTRIBUTIONCHANNEL, 2018-2030 (USD MILLION)
  • TABLE 45 UK: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 46 UK: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 47 UK: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 48 UK: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 49 FRANCE: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 50 FRANCE: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 51 FRANCE: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52 FRANCE: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 53 ITALY: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54 ITALY: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 55 ITALY: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 56 ITALY: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 57 SPAIN: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 58 SPAIN: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 59 SPAIN: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 60 SPAIN: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 61 REST OF EUROPE: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 62 REST OF EUROPE: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 63 REST OF EUROPE: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 64 REST OF EUROPE: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
  • TABLE 65 ASIA PACIFIC: DERCUM'S DISEASE MARKET, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 66 ASIA PACIFIC: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030(USD MILLION)
  • TABLE 67 ASIA PACIFIC: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030(USD MILLION)
  • TABLE 68 ASIA PACIFIC: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030(USD MILLION)
  • TABLE 69 ASIA PACIFIC: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030(USD MILLION)
  • TABLE 70 CHINA: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030(USD MILLION)
  • TABLE 71 CHINA: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030(USD MILLION)
  • TABLE 72 CHINA: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030(USD MILLION)
  • TABLE 73 CHINA: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030(USD MILLION)
  • TABLE 74 INDIA: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030(USD MILLION)
  • TABLE 75 INDIA: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030(USD MILLION)
  • TABLE 76 INDIA: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030(USD MILLION)
  • TABLE 77 CHINA: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030(USD MILLION)
  • TABLE 78 JAPAN: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030(USD MILLION)
  • TABLE 79 JAPAN: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030(USD MILLION)
  • TABLE 80 JAPAN: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030(USD MILLION)
  • TABLE 81 JAPAN: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030(USD MILLION)
  • TABLE 82 AUSTRALIA: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030(USD MILLION)
  • TABLE 83 AUSTRALIA: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030(USD MILLION)
  • TABLE 84 AUSTRALIA: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030(USD MILLION)
  • TABLE 85 AUSTRALIA: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030(USD MILLION)
  • TABLE 86 SOUTH KOREA: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030(USD MILLION)
  • TABLE 87 SOUTH KOREA: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030(USD MILLION)
  • TABLE 88 SOUTH KOREA: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030(USD MILLION)
  • TABLE 89 SOUTH KOREA: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030(USD MILLION)
  • TABLE 90 REST OF ASIA PACIFIC: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030(USD MILLION)
  • TABLE 91 REST OF ASIA PACIFIC: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030(USD MILLION)
  • TABLE 92 REST OF ASIA PACIFIC: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030(USD MILLION)
  • TABLE 93 REST OF ASIA PACIFIC: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030(USD MILLION)
  • TABLE 94 REST OF THE WORLD: DERCUM'S DISEASE MARKET, BY REGION, 2018-2030(USD MILLION)
  • TABLE 95 REST OF THE WORLD: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030(USD MILLION)
  • TABLE 96 REST OF THE WORLD: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030(USD MILLION)
  • TABLE 97 REST OF THE WORLD: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030(USD MILLION)
  • TABLE 98 REST OF THE WORLD: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030(USD MILLION)
  • TABLE 99 MIDDLE EAST: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030(USD MILLION)
  • TABLE 100 MIDDLE EAST: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030(USD MILLION)
  • TABLE 101 MIDDLE EAST: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030(USD MILLION)
  • TABLE 102 MIDDLE EAST: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030(USD MILLION)
  • TABLE 103 AFRICA: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030(USD MILLION)
  • TABLE 104 AFRICA: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030(USD MILLION)
  • TABLE 105 AFRICA: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030(USD MILLION)
  • TABLE 106 AFRICA: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030(USD MILLION)
  • TABLE 107 LATIN AMERICA: DERCUM'S DISEASE MARKET, BY TREATMENT, 2018-2030(USD MILLION)
  • TABLE 108 LATIN AMERICA: DERCUM'S DISEASE MARKET, BY MEDICATION, 2018-2030(USD MILLION)
  • TABLE 109 LATIN AMERICA: DERCUM'S DISEASE MARKET, BY END-USER, 2018-2030(USD MILLION)
  • TABLE 110 LATIN AMERICA: DERCUM'S DISEASE MARKET, BY DISTRIBUTION CHANNEL, 2018-2030(USD MILLION)
  • TABLE 111 MAJOR PLAYERS IN THE GLOBAL DERCUM'S DISEASE MARKET
  • TABLE 112 PFIZER INC: PRODUCTS OFFERED
  • TABLE 113 ABBVIE, INC: PRODUCTS OFFERED
  • TABLE 114 JOHNSON & JOHNSON SERVICES, INC: PRODUCTS OFFERED
  • TABLE 115 GLAXOSMITHKLINE PLC: PRODUCTS OFFERED
  • TABLE 116 BAUSCH & LOMB INCORPORATED: PRODUCTS OFFERED
  • TABLE 117 3M: PRODUCTS/SERVICES OFFERED
  • TABLE 118 RAZIEL THERAPEUTICS LTD: PRODUCTS OFFERED
  • TABLE 119 NIVARTA, INC: PRODUCTS OFFERED
  • TABLE 120 BHR PHARMACEUTICALS LTD: PRODUCTS OFFERED
  • TABLE 121 NOVARTIS INTERNATIONAL AG: PRODUCTS OFFERED

LIST OF FIGURES

  • FIGURE 1 MARKET SYNOPSIS
  • FIGURE 2 GLOBAL DERCUM'S DISEASE MARKET STRUCTURE
  • FIGURE 3 BOTTOM-UP AND TOP-DOWN APPROACHES
  • FIGURE 4 MARKET DYNAMICS: ANALYSIS OF THE GLOBAL DERCUM'S DISEASE MARKET
  • FIGURE 5 DRIVER IMPACT ANALYSIS
  • FIGURE 6 RESTRAINT IMPACT ANALYSIS
  • FIGURE 7 VALUE CHAIN ANALYSIS: GLOBAL DERCUM'S DISEASE MARKET
  • FIGURE 8 PORTER'S FIVE FORCES ANALYSIS: GLOBAL DERCUM'S DISEASE MARKET
  • FIGURE 9 GLOBAL: DERCUM'S DISEASE MARKET, BY TREATMENT, 2022 & 2030 (USD MILLION)
  • FIGURE 10 GLOBAL: DERCUM'S DISEASE MARKET, BY END-USER, 2022 & 2030 (USD MILLION)
  • FIGURE 11 GLOBAL: DERCUM'S DISEASE MARKET, BY DISTRIBUTIONCHANNEL, 2022 & 2030 (USD MILLION)
  • FIGURE 12 GLOBAL: DERCUM'S DISEASE MARKET, BY REGION 2022 & 2030 (USD MILLION)
  • FIGURE 13 GLOBAL: DERCUM'S DISEASE MARKET SHARE (%), BY REGION, 2022
  • FIGURE 14 NORTH AMERICA: DERCUM'S DISEASE MARKET, BY COUNTRY 2022 & 2030 (USD MILLION)
  • FIGURE 15 NORTH AMERICA: DERCUM'S DISEASE MARKET SHARE (%), BY COUNTRY 2022
  • FIGURE 16 EUROPE: DERCUM'S DISEASE MARKET, BY COUNTRY 2022 & 2030 (USD MILLION)
  • FIGURE 17 EUROPE: DERCUM'S DISEASE MARKET SHARE (%), BY COUNTRY 2022
  • FIGURE 18 ASIA PACIFIC DERCUM'S DISEASE MARKET SHARE, BY COUNTRY 2022 & 2030 (USD MILLION)
  • FIGURE 19 ASIA PACIFIC: DERCUM'S DISEASE MARKET SHARE (%), BY COUNTRY, 2022
  • FIGURE 20 REST OF THE WORLD DERCUM'S DISEASE MARKET SHARE, BY REGION 2022 & 2030 (USD MILLION)
  • FIGURE 21 REST OF THE WORLD: DERCUM'S DISEASE MARKET SHARE (%), BY REGION, 2022
  • FIGURE 22 BENCHMARKING OF MAJOR COMPETITORS
  • FIGURE 23 SALES (USD MILLION), 2022
  • FIGURE 24 R&D EXPENDITURE (USD MILLION), 2022
  • FIGURE 25 PFIZER INC: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 26 PFIZER INC: SWOT ANALYSIS
  • FIGURE 27 ABBVIE, INC: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 28 JOHNSON & JOHNSON SERVICES, INC: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 29 JOHNSON & JOHNSON SERVICES, INC.: SWOT ANALYSIS
  • FIGURE 30 GLAXOSMITHKLINE PLC: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 31 GLAXOSMITHKLINE PLC: SWOT ANALYSIS
  • FIGURE 32 BAUSCH & LOMB INCORPORATED: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 33 NIVARTA, INC: SWOT ANALYSIS
  • FIGURE 34 NOVARTIS INTERNATIONAL AG: FINANCIAL OVERVIEW SNAPSHOT
  • FIGURE 35 NOVARTIS INTERNATIONAL AG: SWOT ANALYSIS